AstrraZeneca Announced Earlier Tagrisso Granted Priority Review In The US For Patients With Unresectable, Stage III EGFR-mutated Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso has been granted Priority Review in the US for treating adult patients with unresectable, Stage III EGFR-mutated non-small cell lung cancer after chemoradiotherapy. If approved, Tagrisso will be indicated for patients with specific genetic mutations.
June 10, 2024 | 9:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Tagrisso has been granted Priority Review in the US for treating unresectable, Stage III EGFR-mutated lung cancer. This could lead to an expanded market for Tagrisso if approved.
The Priority Review status indicates that the FDA sees significant potential in Tagrisso for treating a specific type of lung cancer. If approved, this could lead to increased sales and market share for AstraZeneca, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100